Trials / Completed
CompletedNCT02721589
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
An Open-Label, Multiple Centers, Non-randomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multiple centers, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors The primary objective is to assess safety and tolerability of SHR-1210 and identify recommended phase II doses of SHR-1210 in patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SHR-1210 | A fully human monoclonal immunoglobulin (IgG4 subtype) |
Timeline
- Start date
- 2016-04-06
- Primary completion
- 2019-11-17
- Completion
- 2019-11-17
- First posted
- 2016-03-29
- Last updated
- 2023-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02721589. Inclusion in this directory is not an endorsement.